Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q4 FY25 results · Jan–Mar 2025
Emcure Pharmaceuticals reported revenue from operations of ₹2,116.24 crore and net profit of ₹197.24 crore for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,116.24 | — | — | 1,962.63 | +7.8% |
| Other income | 4.45 | — | — | 3.90 | +14.3% |
| Total income | 2,120.70 | — | — | 1,966.53 | +7.8% |
| Profit before tax | 260.61 | — | — | 229.92 | +13.3% |
| Net profit for the period | 197.24 | — | — | 156.09 | +26.4% |
| Attributable to shareholders of the company | 188.96 | — | — | 153.72 | +22.9% |
| EPS, basic (₹) | 9.97 | — | — | 8.12 | +22.8% |
| Net margin (%) | 9.3 | — | 8.0 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,278.19 | — | — | 1,028.81 | +24.2% |
| Other income | 22.40 | — | — | 19.41 | +15.4% |
| Total income | 1,300.58 | — | — | 1,048.22 | +24.1% |
| Profit before tax | 186.05 | — | — | 67.25 | +176.6% |
| Net profit for the period | 139.56 | — | — | 50.20 | +178.0% |
| EPS, basic (₹) | 7.37 | — | — | 2.65 | +178.1% |
| Net margin (%) | 10.9 | — | 4.9 |
Consolidated
- Filed with BSE
- 22 May 2025, 20:28 IST
- Board meeting
- 22 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2025, 20:28 IST
- Board meeting
- 22 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE